A
Abolis Biotechnologies
Designs, Builds and Secure novel bio-processes for renewable chemical production with the help of engineered microbes
About Abolis Biotechnologies
Abolis is an industrial biotechnology company specializing in the development of bioproduction processes for chemical molecules via biomass fermentation. The company serves clients in the Chemical, Pharma, Cosmetic, and Food industries, addressing the challenge of producing ingredients and raw materials sustainably from economic, environmental, and societal perspectives. Abolis leverages its expertise in synthetic biology, informatics, robotics, fermentation, and analytical chemistry to create bio-based and clean alternatives to harmful chemicals. The business model revolves around providing tailored fermentation solutions that transform sugars into specific molecules of interest for their clients. Revenue is generated through project-based collaborations and the commercialization of proprietary bioprocess technologies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Évry-Courcouronnes, France
- Employees
- 69
- Open positions
- 11
- Dealroom signal
- 87.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Synthetic Biology, Spinout, Sustainable Development Goals, Fermentation, Climate Tech, biotech medtech and e-health, Observatoire Deeptech
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Sep 2024 | $39M | $154M | Icos Capital · Liberset · Evonik Venture Capital · L'Oreal BOLD | ↗ |
| SEEDEquity / VC | Apr 2017 | $1.2M | $4.8M | Undisclosed | — |
Growth signals
Latest recorded traffic for Abolis Biotechnologies is 1.5K monthly website visits, up 102.7% over the last three months. Abolis Biotechnologies's team grew 15% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
Evonik Venture Capital
L'Oreal BOLD
DeepTech & Climate Fonds
Icos Capital
Liberset
Clay Capital
Other known investors5 additional known investors
Evry-Val d'Essonne University - Paris-Saclay University
Paris-Saclay University
SATT LUTECH
Sorbonne University
Medevice
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abolis Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abolis Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.